<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437995</url>
  </required_header>
  <id_info>
    <org_study_id>ADV115922</org_study_id>
    <nct_id>NCT01437995</nct_id>
  </id_info>
  <brief_title>Long-acting Beta Agonist Step Down Study</brief_title>
  <acronym>LASST</acronym>
  <official_title>Long-acting Beta Agonist Step Down Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Lung Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 56-week, multi-center, blinded, randomized, double-masked parallel group
      comparative effectiveness study of approaches to stepping down therapy for patients with
      well-controlled asthma treated with combination ICS and LABA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current asthma guidelines recommend stepping down therapy once asthma is controlled for at
      least 3 months. For patients treated with inhaled corticosteroids (ICS) alone, a dose
      reduction of 25-50% to a minimal dose that controls disease is recommended. The optimal
      approach to reducing treatment in patients with asthma treated with combination inhaled
      corticosteroids and long-acting beta agonists (ICS/LABA) is not clear. The American Lung
      Association Asthma Clinical Research Center (ALAACRC) is a network of 18 asthma research
      centers with the goal of performing clinical trials directly relevant to clinical practice.
      The question of the optimal way to de-escalate therapy in patients with asthma that is well
      controlled on fixed dose combination ICS/LABA is a key question for practitioners caring for
      patients with moderate to severe persistent asthma. We propose a 56 week multi-center,
      prospective, randomized, three-arm parallel group comparative effectiveness study comparing
      three approaches to care of patients with asthma well-controlled for three months on
      combination ICS/LABA: reduction of ICS dose and maintenance of LABA, initial discontinuation
      of LABA with continuation of ICS, and continuation of stable dose ICS/LABA. Our primary goal
      is to perform a pragmatic study that resembles clinical practice and determine the optimal
      treatment strategy that results in the lowest rate of treatment failure over 48 weeks of
      follow-up. Additional exploratory analyses include assessing risk factors for step-down
      failure, and to assess the duration of time that asthma control is maintained when therapy is
      de-escalated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>Rate of treatment failures assessed by decline in peak flow or FEV1, increased need for beta agonists, requirement for non-scheduled medical care for asthma symptoms, or prednisone taper.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function- Change in Peak Expiratory Flow</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in morning peak expiratory flow rate from the patients' daily diary cards, calculated at 48 weeks minus baseline (randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Episodes of Poor Asthma Control</measure>
    <time_frame>48 weeks</time_frame>
    <description>Rate of episodes of poor asthma control (EPAC) defined by unscheduled medical care, hospitalization, use of oral corticosteroids and/or increased use of rescue medications and/or decrease of 30% or more in morning peak expiratory flow rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function: FEV1 and FVC</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in participant's pre-bronchodilator pulmonary function tests (FEV1 and FVC) calculated as 48 weeks minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: Change in FEV1/FVC Ratio</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Change in participant's FEV1/FVC ratio calculated as 48 weeks minus baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone/Salmeterol Diskus 250/50 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone/Salmeterol Diskus 100/50 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Diskus alone 250 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/Salmeterol Diskus</intervention_name>
    <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
    <arm_group_label>Fluticasone/Salmeterol Diskus 250/50 ug</arm_group_label>
    <other_name>Fluticasone</other_name>
    <other_name>Salmeterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/Salmeterol Diskus</intervention_name>
    <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
    <arm_group_label>Fluticasone/Salmeterol Diskus 100/50 ug</arm_group_label>
    <other_name>Fluticasone</other_name>
    <other_name>Salmeterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Diskus</intervention_name>
    <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
    <arm_group_label>Fluticasone Diskus alone 250 ug</arm_group_label>
    <other_name>Fluticasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 12-80 years

          -  physician diagnosed asthma that is well-controlled on moderate dose ICS/LABA based on
             an Asthma Control Test (ACT) score more than or equal to 20, and the absence of
             unscheduled visits or use of rescue prednisone for 4 weeks prior to enrollment

          -  pre-bronchodilator FEV1 (forced expiratory volume in 1 second) more than or equal to
             70% predicted

        Exclusion Criteria:

          -  chronic oral steroid therapy

          -  hospitalization or urgent care visit within 4 weeks of the screening visit

          -  lung disease other than asthma including COPD, bronchiectasis, sarcoidosis or other
             lung disease

          -  less than 10 pack/yr of tobacco use and abstinence for at least 1 yr

          -  history of extensive environmental tobacco exposure or occupational exposure
             suggestive of possible COPD (chronic obstructive pulmonary disease) per judgment of
             investigator

          -  post bronchodilator FEV1 less than 70% predicted

          -  near fatal asthma (intubation or ICU admission for asthma) within 2 yrs of enrollment

          -  high risk of near fatal or fatal asthma

          -  history of known premature birth less than 33 weeks or any significant level of
             respiratory care including prolonged oxygen administration or mechanical ventilation
             during the neonatal period

          -  unstable cardiac disease (decompensated congestive heart failure, unstable angina,
             recent myocardial infarction, atrial fibrillation, supraventricular or ventricular
             tachycardia, congenital heart disease, or severe uncontrolled hypertension)

          -  other major chronic illnesses which in the judgment of the study physician would
             interfere with participation in the study e.g. including but not limited to
             uncontrolled diabetes, uncontrolled HIV infection or other immune system disorder

          -  drug allergies to any component of study drug or history of adverse reaction to short
             or long acting beta agonists

          -  for women of child bearing potential; not pregnant, not lactating and agree to
             practice an adequate birth control method (abstinence, combination barrier and
             spermicide, or hormonal) for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Wise, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Rogers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona, Arizona Respiratory Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Illinois Consortium</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Healthcare</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Care Center, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri, Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hofstra North Shore-LIJ School of Medicine</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New England Consortium</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lungusa.org/</url>
    <description>American Lung Association</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <results_first_submitted>October 7, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Robert A. Wise</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Step down therapy</keyword>
  <keyword>Inhaled corticosteroids</keyword>
  <keyword>Long-acting beta agonists</keyword>
  <keyword>Fluticasone Salmeterol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrolled participants were enrolled in an 8-week open label treatment run-in and were subsequently randomized only if their asthma remained stable (i.e. an ACT score ≥ 20 at weeks 4 &amp; 8, no unscheduled healthcare encounters, no change in asthma medication, pre-bronchodilator FEV1 ≥ 70% predicted, and limited use of rescue beta-agonist).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stable ICS-LABA</title>
          <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Fluticasone/Salmeterol Diskus: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
        </group>
        <group group_id="P2">
          <title>Reduced ICS/LABA</title>
          <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Fluticasone/Salmeterol Diskus: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
        </group>
        <group group_id="P3">
          <title>LABA Step Off</title>
          <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Fluticasone Diskus: Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included in Treatment Failure Analysis</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="146"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stable ICS-LABA</title>
          <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Fluticasone/Salmeterol Diskus: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
        </group>
        <group group_id="B2">
          <title>Reduced ICS/LABA</title>
          <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Fluticasone/Salmeterol Diskus: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
        </group>
        <group group_id="B3">
          <title>LABA Step Off</title>
          <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Fluticasone Diskus: Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="155"/>
            <count group_id="B4" value="455"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="22" upper_limit="51"/>
                    <measurement group_id="B2" value="33" lower_limit="17" upper_limit="49"/>
                    <measurement group_id="B3" value="35" lower_limit="23" upper_limit="50"/>
                    <measurement group_id="B4" value="35" lower_limit="20" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoke exposure</title>
          <description>History of cigarette smoking and current exposure to secondhand smoke. Individuals with no history of cigarette smoking and no current exposure to second hand smoke are not counted.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Former smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondhand smoke home/work</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma characteristics</title>
          <description>Description of characteristics of recent asthma treatment. Individuals who did not have a history of the treatment were not counted.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hospitalized for asthma in past year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral steroids in past year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily short-acting beta agonist use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily anti-leukotriene use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of Asthma Onset</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="3" upper_limit="21"/>
                    <measurement group_id="B2" value="7" lower_limit="2" upper_limit="18"/>
                    <measurement group_id="B3" value="7" lower_limit="2" upper_limit="20"/>
                    <measurement group_id="B4" value="7" lower_limit="2" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eNO (exhaled nitric oxide)</title>
          <units>parts per billion</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.5" lower_limit="12.5" upper_limit="26.5"/>
                    <measurement group_id="B2" value="17.5" lower_limit="13.8" upper_limit="25.3"/>
                    <measurement group_id="B3" value="16.5" lower_limit="11.5" upper_limit="26.5"/>
                    <measurement group_id="B4" value="17.5" lower_limit="12.5" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atopy (phadiatop ≥ 0.35 kUA/l)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Symptom Utility Index</title>
          <description>The Asthma Symptom Utility Index asks about asthma symptoms within the past 2 weeks. The scale ranges from 0 to 1 with higher scores indicating better health.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.95" lower_limit="0.90" upper_limit="1.00"/>
                    <measurement group_id="B2" value="0.94" lower_limit="0.89" upper_limit="1.00"/>
                    <measurement group_id="B3" value="0.98" lower_limit="0.92" upper_limit="1.00"/>
                    <measurement group_id="B4" value="0.95" lower_limit="0.89" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulmonary function measures</title>
          <units>Liters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Pre-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.82" lower_limit="2.24" upper_limit="3.31"/>
                    <measurement group_id="B2" value="2.86" lower_limit="2.35" upper_limit="3.44"/>
                    <measurement group_id="B3" value="2.82" lower_limit="2.38" upper_limit="3.49"/>
                    <measurement group_id="B4" value="2.83" lower_limit="2.30" upper_limit="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.54" lower_limit="2.99" upper_limit="4.30"/>
                    <measurement group_id="B2" value="3.62" lower_limit="2.97" upper_limit="4.54"/>
                    <measurement group_id="B3" value="3.65" lower_limit="3.03" upper_limit="4.56"/>
                    <measurement group_id="B4" value="3.62" lower_limit="3.00" upper_limit="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.88" lower_limit="2.34" upper_limit="3.36"/>
                    <measurement group_id="B2" value="2.96" lower_limit="2.39" upper_limit="3.50"/>
                    <measurement group_id="B3" value="2.93" lower_limit="2.44" upper_limit="3.60"/>
                    <measurement group_id="B4" value="2.92" lower_limit="2.39" upper_limit="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.59" lower_limit="3.09" upper_limit="4.28"/>
                    <measurement group_id="B2" value="3.72" lower_limit="3.11" upper_limit="4.63"/>
                    <measurement group_id="B3" value="3.65" lower_limit="3.06" upper_limit="4.52"/>
                    <measurement group_id="B4" value="3.62" lower_limit="3.09" upper_limit="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulmonary function measures, percent predicted</title>
          <units>percent predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Pre-bronchodilator FEV1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="B2" value="91" lower_limit="83" upper_limit="101"/>
                    <measurement group_id="B3" value="92" lower_limit="83" upper_limit="101"/>
                    <measurement group_id="B4" value="91" lower_limit="83" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator FVC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98" lower_limit="89" upper_limit="107"/>
                    <measurement group_id="B2" value="100" lower_limit="91" upper_limit="107"/>
                    <measurement group_id="B3" value="98" lower_limit="90" upper_limit="108"/>
                    <measurement group_id="B4" value="99" lower_limit="90" upper_limit="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator peak flow</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96" lower_limit="84" upper_limit="110"/>
                    <measurement group_id="B2" value="100" lower_limit="90" upper_limit="110"/>
                    <measurement group_id="B3" value="98" lower_limit="89" upper_limit="113"/>
                    <measurement group_id="B4" value="98" lower_limit="88" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other conditions, based upon self-report</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Eczema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic rhinitis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Food allergies</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergies worsen asthma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-bronchodilator peak flow</title>
          <units>Liters per minute</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="420" lower_limit="350" upper_limit="500"/>
                    <measurement group_id="B2" value="430" lower_limit="350" upper_limit="500"/>
                    <measurement group_id="B3" value="430" lower_limit="360" upper_limit="500"/>
                    <measurement group_id="B4" value="430" lower_limit="350" upper_limit="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Control Test Score</title>
          <description>The Asthma Control Test is a validated self-administered survey utilizing 5 questions to assess asthma control on a scale from 1 (poor control) to 5 (total control) in individuals 12 years and older. By answering all 5 questions a patient with asthma can obtain a score that may range between 5 and 25. Asthma control is considered a good characteristic for a person with asthma and therefore a higher score is considered a better outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="22" upper_limit="25"/>
                    <measurement group_id="B2" value="23" lower_limit="21" upper_limit="24"/>
                    <measurement group_id="B3" value="23" lower_limit="22" upper_limit="24"/>
                    <measurement group_id="B4" value="23" lower_limit="22" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marks AQLQ</title>
          <description>Marks Asthma Quality of Life Questionnaire (AQLQ) measures physical and emotional asthma specific quality of life during the past four weeks. The minimum score is 0 and the maximum score is 80, with lower scores indicating better quality of life. The scale is for use in adults only (individuals aged 18 or older).</description>
          <population>The Marks AQLQ is for adults only and was only administered to adult participants (individuals age 18 or older).</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="120"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="125"/>
                    <count group_id="B4" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="1.5" upper_limit="8.0"/>
                    <measurement group_id="B2" value="5.0" lower_limit="2.0" upper_limit="9.0"/>
                    <measurement group_id="B3" value="4.0" lower_limit="2.0" upper_limit="7.0"/>
                    <measurement group_id="B4" value="4.0" lower_limit="2.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Children's Health Survey for Asthma - Child Version</title>
          <description>The Children's Health Survey for Asthma - Child Version (CHSA-C) is a self-reported measure of functional impairments that are most troublesome to children 12 to 17 years of age as a results of their asthma over the past three weeks. Results are reported in Physical, Activity, and Emotion domains. For all domains, the minimum value is 0 and the maximum value is 100, with higher values indicating better health or more positive outcomes.</description>
          <population>The Children's Health Survey for Asthma - Child Version (CHSA-C) is for use in individuals under the age of 18 only. The CHSA-C was administered only to those participants under the age of 18 in our study.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Physical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="B2" value="93" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="B3" value="96" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="B4" value="93" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="B2" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="B3" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="B4" value="100" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93" lower_limit="86" upper_limit="98"/>
                    <measurement group_id="B2" value="95" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="B3" value="93" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="B4" value="93" lower_limit="89" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Euroqual EQ-5D-5L</title>
          <description>The Euroqual EQ-5D-5L is a self-completed generic instrument for measuring quality of life over five dimensions - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The minimum score is 0 and the maximum score is 1, with higher scores indicating better quality of life or better health state.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="155"/>
                    <count group_id="B4" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.00" lower_limit="0.86" upper_limit="1.00"/>
                    <measurement group_id="B2" value="1.00" lower_limit="0.86" upper_limit="1.00"/>
                    <measurement group_id="B3" value="1.00" lower_limit="0.86" upper_limit="1.00"/>
                    <measurement group_id="B4" value="1.00" lower_limit="0.86" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failure</title>
        <description>Rate of treatment failures assessed by decline in peak flow or FEV1, increased need for beta agonists, requirement for non-scheduled medical care for asthma symptoms, or prednisone taper.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stable ICS-LABA</title>
            <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Fluticasone/Salmeterol Diskus: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
          </group>
          <group group_id="O2">
            <title>Reduced ICS/LABA</title>
            <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Fluticasone/Salmeterol Diskus: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
          </group>
          <group group_id="O3">
            <title>LABA Step Off</title>
            <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Fluticasone Diskus: Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure</title>
          <description>Rate of treatment failures assessed by decline in peak flow or FEV1, increased need for beta agonists, requirement for non-scheduled medical care for asthma symptoms, or prednisone taper.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function- Change in Peak Expiratory Flow</title>
        <description>Change in morning peak expiratory flow rate from the patients' daily diary cards, calculated at 48 weeks minus baseline (randomization)</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stable ICS-LABA</title>
            <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Fluticasone/Salmeterol Diskus: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
          </group>
          <group group_id="O2">
            <title>Reduced ICS/LABA</title>
            <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Fluticasone/Salmeterol Diskus: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
          </group>
          <group group_id="O3">
            <title>LABA Step Off</title>
            <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Fluticasone Diskus: Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function- Change in Peak Expiratory Flow</title>
          <description>Change in morning peak expiratory flow rate from the patients' daily diary cards, calculated at 48 weeks minus baseline (randomization)</description>
          <units>Liters per minute</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" lower_limit="-8.10" upper_limit="7.94"/>
                    <measurement group_id="O2" value="4.40" lower_limit="-3.46" upper_limit="12.26"/>
                    <measurement group_id="O3" value="-14.16" lower_limit="-23.1" upper_limit="-5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Episodes of Poor Asthma Control</title>
        <description>Rate of episodes of poor asthma control (EPAC) defined by unscheduled medical care, hospitalization, use of oral corticosteroids and/or increased use of rescue medications and/or decrease of 30% or more in morning peak expiratory flow rate</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stable ICS-LABA</title>
            <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Fluticasone/Salmeterol Diskus: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
          </group>
          <group group_id="O2">
            <title>Reduced ICS/LABA</title>
            <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Fluticasone/Salmeterol Diskus: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
          </group>
          <group group_id="O3">
            <title>LABA Step Off</title>
            <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Fluticasone Diskus: Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Episodes of Poor Asthma Control</title>
          <description>Rate of episodes of poor asthma control (EPAC) defined by unscheduled medical care, hospitalization, use of oral corticosteroids and/or increased use of rescue medications and/or decrease of 30% or more in morning peak expiratory flow rate</description>
          <units>Episodes of poor asthma control</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulmonary Function: FEV1 and FVC</title>
        <description>Change in participant's pre-bronchodilator pulmonary function tests (FEV1 and FVC) calculated as 48 weeks minus baseline.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stable ICS-LABA</title>
            <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Fluticasone/Salmeterol Diskus: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
          </group>
          <group group_id="O2">
            <title>Reduced ICS/LABA</title>
            <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Fluticasone/Salmeterol Diskus: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
          </group>
          <group group_id="O3">
            <title>LABA Step Off</title>
            <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Fluticasone Diskus: Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Function: FEV1 and FVC</title>
          <description>Change in participant's pre-bronchodilator pulmonary function tests (FEV1 and FVC) calculated as 48 weeks minus baseline.</description>
          <units>Liters</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.07" upper_limit="0.03"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.12" upper_limit="-0.01"/>
                    <measurement group_id="O3" value="-0.13" lower_limit="-0.18" upper_limit="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator FVC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.06" upper_limit="0.04"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.10" upper_limit="0.01"/>
                    <measurement group_id="O3" value="-0.09" lower_limit="-0.14" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparing change in pre-bronchodilator FEV1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparing change in pre-bronchodilator FEV1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparing change in pre-bronchodilator FEV1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of change in pre-bronchodilator FVC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of change in pre-bronchodilator FVC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of change in pre-bronchodilator FVC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function: Change in FEV1/FVC Ratio</title>
        <description>Change in participant's FEV1/FVC ratio calculated as 48 weeks minus baseline.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stable ICS-LABA</title>
            <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Fluticasone/Salmeterol Diskus: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
          </group>
          <group group_id="O2">
            <title>Reduced ICS/LABA</title>
            <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Fluticasone/Salmeterol Diskus: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
          </group>
          <group group_id="O3">
            <title>LABA Step Off</title>
            <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Fluticasone Diskus: Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function: Change in FEV1/FVC Ratio</title>
          <description>Change in participant's FEV1/FVC ratio calculated as 48 weeks minus baseline.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" lower_limit="-0.009" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.009" lower_limit="-0.016" upper_limit="-0.002"/>
                    <measurement group_id="O3" value="-0.02" lower_limit="-0.028" upper_limit="-0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of change in FEV1/FVC ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of change in FEV1/FVC ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of change in FEV1/FVC ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>Adverse events were assessed via a questionnaire in the clinic visit form, which was completed at every visit. Adverse events were recorded for participants who had newly detected moderate or severe symptoms after baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stable ICS-LABA</title>
          <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Fluticasone/Salmeterol Diskus: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
        </group>
        <group group_id="E2">
          <title>Reduced ICS/LABA</title>
          <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Fluticasone/Salmeterol Diskus: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
        </group>
        <group group_id="E3">
          <title>LABA Step Off</title>
          <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Fluticasone Diskus: Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated blood sugar</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Graves' Disease, diagnosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Partial small bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee replacement (planned)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure, resolved</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chest discomfort, shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Increased/irregular heartbeat</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="151"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="149"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="38" subjects_at_risk="151"/>
                <counts group_id="E2" events="29" subjects_affected="24" subjects_at_risk="149"/>
                <counts group_id="E3" events="40" subjects_affected="37" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Restlessness or nervousness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="151"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="149"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="151"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="149"/>
                <counts group_id="E3" events="27" subjects_affected="26" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="48" subjects_affected="45" subjects_at_risk="151"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="149"/>
                <counts group_id="E3" events="48" subjects_affected="46" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="151"/>
                <counts group_id="E2" events="37" subjects_affected="35" subjects_at_risk="149"/>
                <counts group_id="E3" events="35" subjects_affected="34" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="151"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="149"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="149"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="55" subjects_affected="53" subjects_at_risk="151"/>
                <counts group_id="E2" events="59" subjects_affected="56" subjects_at_risk="149"/>
                <counts group_id="E3" events="61" subjects_affected="58" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Runny nose/congestion</sub_title>
                <counts group_id="E1" events="60" subjects_affected="52" subjects_at_risk="151"/>
                <counts group_id="E2" events="58" subjects_affected="48" subjects_at_risk="149"/>
                <counts group_id="E3" events="55" subjects_affected="52" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin bruising</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>At the time of this release, this data has not undergone peer-review.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alexis Rea</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4432878496</phone>
      <email>area5@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

